Citalopram Hydrobromide
The hydrobromide salt is the standard oral formulation of citalopram used clinically for depression and anxiety disorders. It shares the same SSRI mechanism and dose-dependent QT prolongation risk as the parent compound. Gradual dose titration is recommended to minimize side effects including nausea and activation symptoms.
Moleküler Ağırlık
405,3000 g/mol
TPSA
36,30 Ų
Terapötik Alanlar
Etki Mekanizması
Selectively inhibits the serotonin reuptake transporter (SERT) at presynaptic neurons, increasing serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is associated with antidepressant and anxiolytic effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits the serotonin reuptake transporter (SERT) at presynaptic neurons, increasing serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is associated with antidepressant and anxiolytic effects.
2D Yapı
Cite this structure
Embed this structure
SMILES
Br.CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
InChI
InChI=1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H
Molecular Formula
C20H22BrFN2O
HBD / HBA
1 / 4
Döndürülebilir Bağlar
5
Ağır Atomlar
25
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
The hydrobromide salt is the standard oral formulation of citalopram used clinically for depression and anxiety disorders. It shares the same SSRI mechanism and dose-dependent QT prolongation risk as the parent compound. Gradual dose titration is recommended to minimize side effects including nausea and activation symptoms.
Selectively inhibits the serotonin reuptake transporter (SERT) at presynaptic neurons, increasing serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is associated with antidepressant and anxiolytic effects.
Yes, Citalopram Hydrobromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200781. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 77995. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="citalopram-hydrobromide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/citalopram-hydrobromide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/citalopram-hydrobromide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/citalopram-hydrobromide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="citalopram-hydrobromide"></drugfyi-drug>